IDEAS home Printed from https://ideas.repec.org/a/lrk/eeaart/22_2_6.html
   My bibliography  Save this article

Committing to Vaccine R&D: A Global Science Policy Priority/Comprometerse en la investigación y desarrollo de vacunas: una prioridad de la política científica global

Author

Listed:
  • ARCHIBUGI, DANIELE

    () (Consiglio Nazionale delle Ricerche and London School of Economics and Political Science. Centre for the Study of Global Governance. Via dei Taurini, 19 00185 Roma. Houghton Street, London W2A 2AE; Telf.: +39-0649937838 – Fax +39-064463836)

  • .KIM BIZZARRI

    () (Consiglio Nazionale delle Ricerche and London School of Economics and Political Science. Centre for the Study of Global Governance.Telf.: +44(0)20 7955 7434 – Fax +44(0)2079557591.)

Abstract

The amount of vaccine R&D performed, especially geared towards health issues affecting the developing world, is exceptionally undersized. Despite immunisation representing the most effective tool for achieving disease eradication, and the general consensus being optimistic about the development of a vaccine capable of fighting AIDS, Malaria and Tuberculosis, neither private nor public entities are investing sufficiently in the field. Reasons can be associated both with a lack of market incentives as well as with the low priority that these diseases set on Western political agendas. Though, seen through the Global Public Good lenses, it appears in the interest of high-income countries, their governments in primis, to invest public resources – financial and infra-structural – in vaccine R&D for global pandemics, as well as managing international cooperation through a global fund. The paper reviews a number of proposals put forward in the existing literature and offers a range of policy options. La cuantía invertida en I+D en vacunas, especialmente dirigida a cuestiones de salud que afectan al mundo en desarrollo, es excepcionalmente insuficiente. A pesar de que la inmunización representa el instrumento más efectivo para lograr la erradicación de enfermedades, y de que el consenso general es optimista sobre el desarrollo de una vacuna capaz de luchar contra el SIDA, la malaria y la tuberculosis, ni las entidades públicas ni las privadas están invirtiendo lo suficiente en este campo. Las razones de ello pueden asociarse tanto con una falta de incentivos de mercado como también con la baja prioridad que esas enfermedades tienen en las agendas políticas de Occidente. Si bien, visto desde la óptica de los Bienes Públicos Globales, parece que sería del interés de los países de rentas altas, e in primis de sus Gobiernos, el invertir recursos públicos – financieros y de infraestructura – en I+D en vacunas para las pandemias globales, así como gestionar la cooperación internacional por medio de un fondo global. Este trabajo revisa un conjunto de propuestas recogidas en la bibliografía existente, ofreciendo un conjunto de opciones de política al respecto.

Suggested Citation

  • Archibugi, Daniele & .Kim Bizzarri, 2004. "Committing to Vaccine R&D: A Global Science Policy Priority/Comprometerse en la investigación y desarrollo de vacunas: una prioridad de la política científica global," Estudios de Economía Aplicada, Estudios de Economía Aplicada, vol. 22, pages 251-271, Agosto.
  • Handle: RePEc:lrk:eeaart:22_2_6
    as

    Download full text from publisher

    File URL: http://www.revista-eea.net
    Download Restriction: Access to full text is restricted to subscribers.

    As the access to this document is restricted, you may want to look for a different version below or search for a different version of it.

    Other versions of this item:

    References listed on IDEAS

    as
    1. Archibugi, Daniele & Lundvall, Bengt-Ake (ed.), 2001. "The Globalizing Learning Economy," OUP Catalogue, Oxford University Press, number 9780199241095.
    2. Frank, Richard G., 2003. "New estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 325-330, March.
    3. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G. & Lasagna, Louis, 1991. "Cost of innovation in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 10(2), pages 107-142, July.
    4. Kenneth Arrow, 1962. "Economic Welfare and the Allocation of Resources for Invention," NBER Chapters,in: The Rate and Direction of Inventive Activity: Economic and Social Factors, pages 609-626 National Bureau of Economic Research, Inc.
    5. Bengt-ake Lundvall & Bjorn Johnson, 1994. "The Learning Economy," Industry and Innovation, Taylor & Francis Journals, vol. 1(2), pages 23-42.
    6. Mazzoleni, Roberto & Nelson, Richard R., 1998. "The benefits and costs of strong patent protection: a contribution to the current debate," Research Policy, Elsevier, vol. 27(3), pages 273-284, July.
    7. Cockburn, Iain M & Henderson, Rebecca M, 1998. "Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery," Journal of Industrial Economics, Wiley Blackwell, vol. 46(2), pages 157-182, June.
    8. Gambardella, Alfonso & Orsenigo, Luigi & Pammolli, Fabio, 2000. "Global Competitiveness in Pharmaceuticals: A European Perspective," MPRA Paper 15965, University Library of Munich, Germany.
    9. Grabowski, Henry G. & Vernon, John M., 1994. "Returns to R&D on new drug introductions in the 1980s," Journal of Health Economics, Elsevier, vol. 13(4), pages 383-406.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Abdelillah Hamdouch & Marc-Hubert Depret, 2005. "Carences institutionnelles et rationnement de l'accès à la santé dans les pays en développement : repères et enjeux," Mondes en développement, De Boeck Université, vol. 131(3), pages 11-28.
    2. Yaqub, Ohid & Nightingale, Paul, 2012. "Vaccine innovation, translational research and the management of knowledge accumulation," Social Science & Medicine, Elsevier, vol. 75(12), pages 2143-2150.
    3. repec:eee:tefoso:v:127:y:2018:i:c:p:97-111 is not listed on IDEAS
    4. Agata Czaplińska, 2007. "Building Public Support for Development Cooperation," Policy Papers del Instituto Complutense de Estudios Internacionales 07-02, Universidad Complutense de Madrid, Instituto Complutense de Estudios Internacionales.
    5. Srinivas, Smita, 2006. "Industrial Development and Innovation: Some Lessons from Vaccine Procurement," World Development, Elsevier, vol. 34(10), pages 1742-1764, October.

    More about this item

    Keywords

    Science and health policy; Malaria; tuberculosis; HIV/AIDS; neglected diseases; global governance; free-riding; global public goods; vaccine R&D;

    JEL classification:

    • H40 - Public Economics - - Publicly Provided Goods - - - General
    • H41 - Public Economics - - Publicly Provided Goods - - - Public Goods
    • I10 - Health, Education, and Welfare - - Health - - - General

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:lrk:eeaart:22_2_6. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Beatriz Rodríguez Prado). General contact details of provider: http://edirc.repec.org/data/fcvldes.html .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.